Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06470763 · ClinicalTrials.gov registry record · Phase 1
A Study Evaluating ANV600 Single Agent or in Combination with Pembrolizumab in Participants with Advanced Solid Tumors (EXPAND-1)
A Phase 1 study of Advanced Solid Tumor, sponsored by Anaveon.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 240
- Enrollment target
- 18
- Study locations
NCT06470763: Recruiting Phase 1 study of Advanced Solid Tumor, sponsored by Anaveon.
NCT06470763 is a Phase 1 study of Advanced Solid Tumor that is actively recruiting participants, run by Anaveon. The registered enrollment target is 240 participants, above the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (25% higher). The trial reports 18 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06470763, a Phase 1 study of Advanced Solid Tumor, is actively recruiting participants, sponsored by Anaveon.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 240 participants
- Enrollment target
- 18
- Study locations
Study Summary
The purpose of study ANV600-001 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, immunogenicity and antitumor activity of ANV600 administered as a single agent or in combination with pembrolizumab in adult participants with advanced solid tumors.
Conditions Studied
Interventions
- DRUG ANV600
- DRUG ANV600 + pembrolizumab (KEYTRUDA®)
Study Locations (18)
Other
- Cliniques Universitaires Saint-Luc - Brussels
- Institut Bergonie - Bordeaux
- CEPCM - AP-HM Hopital de la Timone - Marseille
- Oncopole Claudius Regaud, Toulouse - Toulouse
- Institut Gustave Roussy - Villejuif
- Charite Universitaetsmedizin Berlin - Berlin
- Krankenhaus Nordwest - Institut für Klinisch-Onkologische Forschung (IKF) - Frankfurt
- Universitaetsmedizin der Johannes Gutenberg - Universitaet Mainz - Mainz
- Nederlands Kanker Instituut - Antoni van Leeuwenhoek (NKI-AVL) - Amsterdam
- Vall d'Hebron Institute of Oncology (VHIO) - Barcelona
- START Madrid CIOCC - Madrid
- Clinica Universidad de Navarra - Pamplona - Pamplona
- INCLIVA Foundation - Valencia
- Ente Ospedaliero Cantonale - Istituto Oncologico della Svizzera Italiana - Bellinzona
- Cantonal Hospital St Gallen - Sankt Gallen
Michigan
- Karmanos Cancer Institute - Detroit
Pennsylvania
- Fox Chase Cancer Center - Philadelphia
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2024-07-01 |
| Est. Completion | 2028-02 |
| Phase | Phase 1 |
What NCT06470763 shows while recruiting
NCT06470763 is an interventional study that assigns participants to a tested intervention. The registered 240 participants enrollment target is mid-sized for trials with a published cap, above the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (25% higher).
The record links to 1 condition, with Advanced Solid Tumor appearing as the primary indexed condition, and to 2 interventions - of which ANV600 is the first listed.
NCT06470763 lists 18 locations in 4 states (Other, Michigan, Pennsylvania).
Frequently Asked Questions
What is clinical trial NCT06470763 about?
NCT06470763 is a clinical study titled "A Study Evaluating ANV600 Single Agent or in Combination with Pembrolizumab in Participants with Advanced Solid Tumors (EXPAND-1)". The purpose of study ANV600-001 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, immunogenicity and antitumor activity of ANV600 administered as a single agent or in combination with pembrolizumab in adult participants with advanced solid tumors.
What is the current status of trial NCT06470763?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 240 participants. The study started on 2024-07-01. Estimated completion is 2028-02.
What conditions does trial NCT06470763 study?
This clinical trial studies the following conditions: Advanced Solid Tumor.
What interventions are being tested in trial NCT06470763?
The interventions under investigation include: ANV600 (DRUG), ANV600 + pembrolizumab (KEYTRUDA®) (DRUG).
Who is sponsoring clinical trial NCT06470763?
This trial is sponsored by Anaveon, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06470763 being conducted?
This trial has 18 study locations across Michigan, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06470763's enrollment target sits among peer trials
240 49th of 189 higher than 139 of 189 other Advanced Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PM14 Administered Intravenously to Patients with Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
RECRUITING · Phase 1
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02855554 · 240 participants · NA
Quantitative Cardiac Parametric Mapping
- NCT03230565 · 240 participants · Phase 4
Continuous Infusions vs Scheduled Bolus Infusions
- NCT03399929 · 240 participants
Traumatic Brain Injury and Stroke Long Term Outcome
- NCT03583710 · 240 participants · Phase 3
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI